FTC eyes resuming insulin lawsuit against drug middlemen
The U.S. Federal Trade Commission's lawsuit against pharmacy benefit managers over insulin pricing practices will likely move ...
Trump’s Move to Dump FTC’s Democratic Members Leaves Insulin Case in Limbo
The Federal Trade Commission’s lawsuit against three large pharmacy-benefit managers over insulin prices is on hold after ...
Fierce Healthcare2d
FTC Chair Ferguson changes course on recusal from PBM insulin case
Federal Trade Commission Chair Andrew Ferguson has reversed course on his decision to recuse himself from the agency's legal ...
The Lund Report3d
Did Trump tank the FTC’s insulin suit? Observers want to know
The Federal Trade Commission late Tuesday stayed a lawsuit accusing pharmacy middlemen of gaming the system to inflate the ...
STAT4d
FTC suit over PBMs’ insulin pricing is delayed in part by Trump firings
A controversial lawsuit brought by the FTC against the largest PBMs over insulin pricing was delayed in part by Trump firings ...
FTC puts hold on insulin lawsuit against drug middlemen
The Federal Trade Commission put on hold a lawsuit against pharmacy-benefit manager (PBM) units of UnitedHealth , Cigna and ...
Ferguson Joins, Restarts FTC Case Targeting PBMs Over Insulin Pricing
The FTC's general counsel had stayed the administrative complaint because the two FTC commissioners—Chair Andrew Ferguson and ...
Seeking Alpha2d
FTC looks to revive insulin lawsuit against pharma middlemen
Chairman of the Federal Trade Commission Andrew Ferguson says he plans to resume a lawsuit alleging that the three leading pharmacy benefit managers in the U.S. ran an illegal scheme that led to ...
FTC Halts In-House Court Case Against Pharmacy Benefit Managers
The Federal Trade Commission has paused an enforcement action alleging pharmacy benefit managers used illegal rebate programs ...
Reuters2d
FTC eyes resuming insulin lawsuit against drug middlemen
April 4 (Reuters) - The U.S. Federal Trade Commission's lawsuit against pharmacy benefit managers over insulin pricing practices will likely move forward again after being paused amid President ...